Francesca Ficara

Dr. Francesca Ficara

UOS Milan Unit, Istituto di Ricerca Genetica e Biomedica (IRGB), CNR, 20138, Milan, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2002 in Science
Verified
Journal Article
Closed access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
SSShimon Slavin
Shimon Slavin
MAMemet Aker
Memet Aker
FFFrancesca Ficara
Francesca Ficara
SDSara Deola
Sara Deola
CBClaudio Bordignon
Claudio Bordignon
Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)–deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

1 May 2008 in Cell Stem Cell
Verified
Journal Article
Closed access
FFFrancesca Ficara
Francesca Ficara
MMMark J. Murphy
Mark J. Murphy
MLMin Lin
Min Lin
MCMichael L. Cleary
Michael L. Cleary

23 October 2003 in Blood
Verified
Journal Article
Open access
PDF file
EZElisabetta Zino
Elisabetta Zino
GFGuido Frumento
Guido Frumento
SMSarah Marktel
Sarah Marktel
MSMaria Pia Sormani
Maria Pia Sormani
FFFrancesca Ficara
Francesca Ficara
KFKatharina Fleischhauer
Katharina Fleischhauer
The importance of HLA-DPB1 matching for the outcome of allogeneic hematologic stem cell (HSC) transplantation is controversial. We have previously identified HLA-DPB1*0901 as a target of cytotoxic T cells mediating in vivo rejection of an HSC allograft. Here we show that HLA-DPB1*0901 encodes a T-cell epitope shared by a subset of DPB1 alleles that determines nonpermissive mismatches for HSC transplantation. Several T-cell clones obtained from the patient at the time of rejection showed HLA-DP restricted recognition of allogeneic targets expressing HLA-DPB1*0901, *1001, *1701, *0301, *1401, and *4501, but not other alleles. Based on these findings, we developed an algorithm for prediction of nonpermissive HLA-DPB1 mismatches. Retrospective evaluation of 118 transplantations showed that the presence of nonpermissive HLA-DPB1 mismatches was correlated with significantly increased hazards of acute grade II to IV graft-versus-host disease (HR = 1.87, P = .046) and transplantation-related mortality (HR = 2.69, P = .027) but not relapse (HR = 0.98, P = .939), as compared with the permissive group. There was also a marked but statistically not significant increase in the hazards of overall mortality (HR = 1.64, P = .1). These data suggest that biologic characterization of in vivo alloreactivity can be a tool for definition of clinically relevant nonpermissive HLA mismatches for unrelated HSC transplantation.

1 May 2002 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
SVSergio Vai
Sergio Vai
AMAlessandra Mortellaro
Alessandra Mortellaro
GCGiulia Casorati
Giulia Casorati
FFFrancesca Ficara
Francesca Ficara
CBClaudio Bordignon
Claudio Bordignon

28 April 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PWPiu Wong
Piu Wong
MIMasayuki Iwasaki
Masayuki Iwasaki
TSTim Somervaille
Tim Somervaille
FFFrancesca Ficara
Francesca Ficara
CCChristine Carico
Christine Carico
MCMichael L. Cleary
Michael L. Cleary
Despite advances in defining the critical molecular determinants for leukemia stem cell (LSC) generation and maintenance, little is known about the roles of microRNAs in LSC biology. Here, we identify microRNAs that are differentially expressed in LSC-enriched cell fractions (c-kit+) in a mouse model of MLL leukemia. Members of the miR-17 family were notably more abundant in LSCs compared with their normal counterpart granulocyte-macrophage progenitors and myeloblast precursors. Expression of miR-17 family microRNAs was substantially reduced concomitant with leukemia cell differentiation and loss of self-renewal, whereas forced expression of a polycistron construct encoding miR-17-19b miRNAs significantly shortened the latency for MLL leukemia development. Leukemias expressing increased levels of the miR-17-19b construct displayed a higher frequency of LSCs, more stringent block of differentiation, and enhanced proliferation associated with reduced expression of p21, a cyclin-dependent kinase inhibitor previously implicated as a direct target of miR-17 microRNAs. Knockdown of p21 in MLL-transformed cells phenocopied the overexpression of the miR-17 polycistron, including a significant decrease in leukemia latency, validating p21 as a biologically relevant and direct in vivo target of the miR-17 polycistron in MLL leukemia. Expression of c-myc, a crucial upstream regulator of the miR-17 polycistron, correlated with miR-17-92 levels, enhanced self-renewal, and LSC potential. Thus, microRNAs quantitatively regulate LSC self-renewal in MLL-associated leukemia in part by modulating the expression of p21, a known regulator of normal stem cell function. Cancer Res; 70(9); 3833–42. ©2010 AACR.

1 June 1999 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
MTManuela Tavian
Manuela Tavian
ACArcadi Cipponi
Arcadi Cipponi
FFFrancesca Ficara
Francesca Ficara
EZElisabetta Zappone
Elisabetta Zappone
CBClaudio Bordignon
Claudio Bordignon